症候性玻璃體黃斑粘連 (VMA) :主要9市場預測 2016-2026年
Symptomatic Vitreomacular Adhesion Forecast in 9 Major Markets 2016-2026
|出版商||Black Swan Analysis||商品編碼||353108|
|出版日期||內容資訊||英文 40 Pages
|症候性玻璃體黃斑粘連 (VMA) :主要9市場預測 2016-2026年 Symptomatic Vitreomacular Adhesion Forecast in 9 Major Markets 2016-2026|
|出版日期: 2016年02月26日||內容資訊: 英文 40 Pages||
本報告提供主要9個市場 (美國、法國、德國、義大利、西班牙、英國、巴西、日本，及印度) 的症候性玻璃體黃斑粘連 (VMA) 的目前患者數 (性別，各年齡世代) 調查分析，目前盛行率，加上疾病概要，危險因素，疾病診斷預後，主要的症狀和併發症等系統性資訊
Symptomatic Vitreomacular adhesion (VMA) is a rare macular condition caused by an incomplete posterior vitreous detachment from the retina, located at the back of the eye, with remaining vitreomacular attachment and unperturbed foveal morphologic features. It is almost always the result of normal vitreous aging, and is termed symptomatic VMA leading to vitreomacular traction because with loss of vitreous volume, these areas of VMA exert a "pulling force" on the macula, causing other pathologic conditions.
This report provides the current prevalent population for symptomatic VMA across 9 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil, Japan and India) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of VMA have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
Main symptoms and co-morbidities for VMA include:
This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.
US, UK, FR, DE, IT, ES, JP, BR, IN